Clinical Characteristics, Response to Platinum-Based Chemotherapy and Poly (Adenosine Phosphate-Ribose) Polymerase Inhibitors in Advanced Lung Cancer Patients Harboring BRCA Mutations

SIMPLE SUMMARY: Carriers of germline BRCA1/2 pathogenic variants are at increased risk of developing BRCA-associated malignancies (breast, ovarian, prostate and pancreatic cancer), which are responsive to treatment with poly (adenosine phosphate-ribose) polymerase inhibitors (PARPi) and platinum-bas...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnon, Johnathan, Tabi, Michael, Rottenberg, Yakir, Zick, Aviad, Blumenfeld, Philip, Hamburger, Tamar, Pikarsky, Eli, Avraham, Eti, Levine, Leeby, Popovtzer, Aron, Yablonski-Peretz, Tamar, Kadouri, Luna, Nechushtan, Hovav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571558/
https://www.ncbi.nlm.nih.gov/pubmed/37835426
http://dx.doi.org/10.3390/cancers15194733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571558/
https://www.ncbi.nlm.nih.gov/pubmed/37835426
http://dx.doi.org/10.3390/cancers15194733

Ejemplares similares